More data evaluated: Astrazeneca insists on vaccine safety

More data evaluated
Astrazeneca insists on vaccine safety

Astrazeneca continues to fight its bad image. After reports of a possible increased risk of blood clots in connection with the vaccine, the vaccine manufacturer feels compelled to act and publishes further data of an analysis in a statement.

The British-Swedish pharmaceutical company Astrazeneca has again rejected concerns about the safety of its corona vaccine after an analysis of vaccination data. A careful analysis of the safety data of more than 17 million people vaccinated in the EU and the UK did not show any evidence of a higher risk of pulmonary embolism, deep vein thrombosis or low platelet counts (thrombocytopenia).

The company is now referring to even more data sets. Astrazeneca had already made the same statement on Friday and referred to ten million records. Denmark and other countries had previously suspended vaccinations with the substance. The reason given was reports of death and serious illness from blood clots after vaccination. However, it was also emphasized that a connection between the vaccine and the blood clots could not yet be established.

“Around 17 million people in the EU and the UK have now received our vaccine and the number of reported cases of blood clots in this group is less than the hundreds of cases that would be expected in the general population,” it said Message. The pandemic has led to increased attention in individual cases. “We go beyond standard practices for monitoring the safety of approved drugs in reporting vaccine incidents to ensure public safety,” added Astrazeneca. In terms of quality, there are no confirmed problems with any batch of the vaccine used in Europe or the rest of the world.

The European Medicines Agency (EMA) also stated at the weekend that there was no noticeable accumulation of thromboses in connection with the vaccination and that the benefits of inoculating the Astrazeneca agent were greater than the risks.

Leave a Comment